USA - NYSEARCA:MYO - US62857J2015 - Common Stock
The current stock price of MYO is 0.8338 USD. In the past month the price decreased by -33.74%. In the past year, price decreased by -85.81%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.85 | 215.82B | ||
| ISRG | INTUITIVE SURGICAL INC | 66 | 203.72B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.06 | 144.50B | ||
| SYK | STRYKER CORP | 27.81 | 140.05B | ||
| IDXX | IDEXX LABORATORIES INC | 55.34 | 55.83B | ||
| BDX | BECTON DICKINSON AND CO | 13.25 | 54.76B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.25 | 50.17B | ||
| RMD | RESMED INC | 24.5 | 35.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.1 | 33.75B | ||
| PODD | INSULET CORP | 72.66 | 23.37B | ||
| DXCM | DEXCOM INC | 32.41 | 23.64B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.05 | 17.71B |
Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 184 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
MYOMO INC
137 Portland Street, 4th Floor
Boston MASSACHUSETTS 02114 US
CEO: Paul R. Gudonis
Employees: 185
Phone: 16179969058
Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 184 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
The current stock price of MYO is 0.8338 USD. The price increased by 15.45% in the last trading session.
MYO does not pay a dividend.
MYO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
MYOMO INC (MYO) has a market capitalization of 31.52M USD. This makes MYO a Nano Cap stock.
You can find the ownership structure of MYOMO INC (MYO) on the Ownership tab.
ChartMill assigns a fundamental rating of 3 / 10 to MYO. Both the profitability and financial health of MYO have multiple concerns.
Over the last trailing twelve months MYO reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS decreased by -26.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.11% | ||
| ROE | -52.93% | ||
| Debt/Equity | 0.22 |
9 analysts have analysed MYO and the average price target is 5.2 USD. This implies a price increase of 523.89% is expected in the next year compared to the current price of 0.8338.
For the next year, analysts expect an EPS growth of -124.58% and a revenue growth 32.66% for MYO